Video

Dr. Vaishampayan highlights new options in second-line urothelial cancer

Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine, professor of internal medicine, University of Michigan, discusses new options available for the second-line treatment of urothelial cancer, including the antibody-drug conjugates enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy).

Related Videos
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.